Echinocandins: the newest class of antifungals (Q34019188)

30 July 2017

1 reference

title

Echinocandins: the newest class of antifungals (English)

1 reference

30 July 2017

Allana J Sucher

1

1 reference

30 July 2017

Elias B Chahine

series ordinal

2

1 reference

30 July 2017

Holly E Balcer

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Annals of Pharmacotherapy

30 July 2017

published in

1 reference

30 July 2017

volume

43

1 reference

30 July 2017

issue

10

1 reference

30 July 2017

page(s)

1647-1657

1 reference

The global epidemiology of invasive Candida infections--is the tide turning?

30 July 2017

cites work

1 reference

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

21 January 2018

1 reference

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications

21 January 2018

1 reference

Echinocandin antifungal drugs

21 January 2018

1 reference

A comparative evaluation of properties and clinical efficacy of the echinocandins

21 January 2018

1 reference

Echinocandins: role in antifungal therapy, 2005.

21 January 2018

1 reference

Micafungin: a new echinocandin

21 January 2018

1 reference

21 January 2018

1 reference

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety

21 January 2018

1 reference

Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

21 January 2018

1 reference

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 January 2018

1 reference

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

21 January 2018

1 reference

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

21 January 2018

1 reference

Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability

21 January 2018

1 reference

In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms

21 January 2018

1 reference

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.

21 January 2018

1 reference

Resistance to echinocandin-class antifungal drugs

21 January 2018

1 reference

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

21 January 2018

1 reference

Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient

21 January 2018

1 reference

Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

21 January 2018

1 reference

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy

21 January 2018

1 reference

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis

21 January 2018

1 reference

Acquired resistance to echinocandins in Candida albicans: case report and review

21 January 2018

1 reference

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

21 January 2018

1 reference

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

21 January 2018

1 reference

Pharmacodynamic implications for use of antifungal agents

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of antifungals

21 January 2018

1 reference

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

21 January 2018

1 reference

Population pharmacokinetics of micafungin in adult patients

21 January 2018

1 reference

Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies

21 January 2018

1 reference

Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis

21 January 2018

1 reference

Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis

21 January 2018

1 reference

Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia

21 January 2018

1 reference

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants

21 January 2018

1 reference

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

21 January 2018

1 reference

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing

21 January 2018

1 reference

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

21 January 2018

1 reference

Early clinical experience with anidulafungin at a large tertiary care medical center

21 January 2018

1 reference

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis

21 January 2018

1 reference

21 January 2018

1 reference

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

21 January 2018

1 reference

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

21 January 2018

1 reference

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M237

1 reference

30 July 2017

1 reference